SGC-CBP30 is primarily used in research settings as a potent, selective, and cell-permeable inhibitor of the bromodomain of CREB-binding protein (CBP) and the related p300 (EP300) histone acetyltransferase. These proteins function as transcriptional co-activators and epigenetic regulators, facilitating gene expression through histone acetylation and bromodomain-mediated recognition of acetylated lysines.

By selectively inhibiting the CBP/p300 bromodomains, SGC-CBP30 enables researchers to dissect the specific roles of these protein modules in cellular processes such as transcription activation, cell proliferation, differentiation, and inflammatory responses, without broadly affecting their acetyltransferase activity.

In cancer research, SGC-CBP30 is particularly useful for investigating the oncogenic functions of CBP/p300, which are frequently dysregulated in tumors. It has demonstrated effects in suppressing tumor cell growth, inducing apoptosis, and modulating pathways like Wnt/β-catenin signaling, aiding in the identification of novel therapeutic strategies.

Additionally, SGC-CBP30 is employed in immunological and inflammatory studies to explore how CBP/p300 regulate cytokine production and immune cell function. It provides insights into potential treatments for autoimmune diseases, chronic inflammation, and fibrosis.

Overall, as a high-quality chemical probe developed by the Structural Genomics Consortium (SGC), SGC-CBP30 is invaluable in chemical biology, epigenetics, and early-stage drug discovery for probing CBP/p300 biology and validating them as drug targets.